Clinical Validation of the Melanoscope AI Mobile Dermoscopy Clinical Decision Support System

Researchers validated the Melanoscope AI clinical decision support system for skin lesion screening in Russian outpatient settings, achieving 88.6% agreement with expert assessment and zero false negatives among malignant cases. The study introduces quantitative interpretability methods for deep learning models and a three-zone patient routing algorithm, demonstrating the viability of AI-powered dermoscopy as a scalable solution to address dermatologist shortages.

The Melanoscope AI validation represents a meaningful advance in deploying interpretable artificial intelligence within resource-constrained healthcare environments. The system addresses a genuine clinical bottleneck: dermatologist shortages in Russian regions limit early melanoma detection, which directly impacts patient survival outcomes. By combining cascade classification with attention-based visualization and quantitative IoU assessment, the researchers created a framework that prioritizes both diagnostic accuracy and clinical transparency—critical factors for physician adoption of AI tools.

The results demonstrate clinical credibility without overselling capability. Zero false negatives among five malignant lesions provides confidence for screening applications, while 88.3% specificity balances sensitivity with manageable false-positive rates. The attention map analysis revealing varying IoU scores across model architectures (ViT at 0.69 versus EfficientNetV2 at 0.51) underscores that interpretability quality differs meaningfully between underlying architectures, a nuance often overlooked in clinical AI discussions.

The three-zone routing algorithm pragmatically addresses real-world deployment: stratifying patients by confidence thresholds enables flexible resource allocation across settings with varying specialist availability. This approach scales beyond dermatology, offering a template for other specialties facing provider shortages.

The prospective validation design, though single-center and preliminary, provides more rigorous evidence than retrospective studies. The upcoming validation phases through April 2026 across multiple "Melanoma Day" sessions will test reproducibility and generalization. Success here positions interpretable cascade models as a viable alternative to black-box approaches in regulated medical environments where clinical explainability increasingly influences regulatory approval and reimbursement.

• →Melanoscope AI achieved 88.6% agreement with expert dermatologists and zero false negatives on malignant lesions, validating safety for screening applications.
• →Quantitative interpretability assessment using attention maps with IoU scoring demonstrates measurable differences in model explainability across architectures.
• →Three-zone patient routing algorithm enables adaptive deployment across healthcare settings with varying specialist availability and resource constraints.
• →Single-center prospective validation in Russian outpatient practice demonstrates practical viability in resource-limited regions facing dermatologist shortages.
• →Attention map quality varies significantly by architecture, with ViT (0.69 IoU) substantially outperforming EfficientNetV2 (0.51 IoU) in interpretability.